Needham & Company upgraded Cytokinetics (NASDAQ: CYTK) from Buy to Strong Buy with a price target of $22.00 (from $17.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE